1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Dvorak, H. F. Angiogenesis: update 2005. J. Thromb. Haemost. 3, 1835–1842 (2005).
Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).
Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4–10 (2005).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Verheul, H. M., Voest, E. E. & Schlingemann, R. O. Are tumours angiogenesis-dependent? J. Pathol.
202, 5–13 (2004).
Zhong, H. & Bowen, J. P. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature.
Curr. Med. Chem. 13, 849–862 (2006).
Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246,
1309–1312 (1989).
Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J. & Dvorak, H. F. Purification and NH2-terminal
amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774–
1778 (1990).
Roy, H., Bhardwaj, S. & Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 580,
2879–2887 (2006).
Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific
for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl. 1),
2–10 (2004).
Holmes, D. I. & Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in
health and disease. Genome Biol. 6, 209 (2005).
Levy, A. P., Levy, N. S. & Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth
factor by hypoxia. J. Biol. Chem. 271, 2746–2753 (1996).
Levy, A. P., Levy, N. S., Wegner, S. & Goldberg, M. A. Transcriptional regulation of the rat vascular
endothelial growth factor gene by hypoxia. J. Biol. Chem. 270, 13333–13340 (1995).
Mukhopadhyay, D., Tsiokas, L. & Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on
human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161–6165 (1995).
Maher, E. R. & Kaelin, W. G., Jr. von Hippel–Lindau disease. Medicine (Baltimore) 76, 381–391 (1997).
Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. v-Src induces expression of hypoxia-inducible
factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1:
involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328–5335 (1997).
Klagsbrun, M. & D’Amore, P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth
Factor Rev. 7, 259–270 (1996).
Shibuya, M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J.
Biochem. Cell Biol. 33, 409–420 (2001).
Wiesmann, C., Muller, Y. A. & de Vos, A. M. Ligand-binding sites in Ig-like domains of receptor tyrosine
kinases. J. Mol. Med. 78, 247–260 (2000).
Schlessinger, J. & Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron 9, 383–391
(1992).
Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor
angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
Karkkainen, M. J. & Petrova, T. V. Vascular endothelial growth factor receptors in the regulation of
angiogenesis and lymphangiogenesis. Oncogene 19, 5598–5605 (2000).
Nagy, J. A. et al. Vascular permeability factor/vascular endothelial growth factor induces
lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497–1506 (2002).
Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203–
212 (1990).
Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther.
315, 971–979 (2005).
Hubbard, S. R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 71, 343–358
(1999).
Sonpavde, G. & Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol.
Rep. 9, 115–119 (2007).
Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T. & Alitalo, K. Vascular endothelial growth factor
receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156, 1499–1504 (2000).
Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling in control of
vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Science STKE 2001, RE21
(2001).
Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is
essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells.
EMBO J. 20, 2768–2778 (2001).
34. Dayanir, V., Meyer, R. D., Lashkari, K. & Rahimi, N. Identification of tyrosine residues in vascular
endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell
proliferation. J. Biol. Chem. 276, 17686–17692 (2001).
35. Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor
in an anchorage-dependent manner. J. Biol. Chem. 274, 16349–16354 (1999).
36. Sakai, R. et al. The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the
maturation of sensory and sympathetic neurons. Neuron 28, 819–833 (2000).
37. Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. & Prigent, S. A. The Shc-related adaptor
protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected
cells. Biochem. J. 347, 501–509 (2000).
38. Shu, X., Wu, W., Mosteller, R. D. & Broek, D. Sphingosine kinase mediates vascular endothelial growth
factor-induced activation of Ras and mitogen-activated protein kinases. Mol. Cell Biol. 22, 7758–7768
(2002).
39. Meadows, K. N., Bryant, P. & Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic
phenotype requires Ras activation. J. Biol. Chem. 276, 49289–49298 (2001).
40. Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent
Raf–MEK–MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230
(1999).
41. Abedi, H. & Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and
recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol.
Chem. 272, 15442–15451 (1997).
42. Le Boeuf, F., Houle, F. & Huot, J. Regulation of vascular endothelial growth factor receptor 2-mediated
phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J. Biol.
Chem. 279, 39175–39185 (2004).
43. Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in
regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
44. Makinen, T. et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via
the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762–4773 (2001).
45. Karkkainen, M. J. et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic
vessels from embryonic veins. Nat. Immunol. 5, 74–80 (2004).
46. Wang, J. F., Zhang, X. & Groopman, J. E. Activation of vascular endothelial growth factor receptor-3 and
its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279, 27088–27097
(2004).
47. Korpelainen, E. I., Karkkainen, M., Gunji, Y., Vikkula, M. & Alitalo, K. Endothelial receptor tyrosine kinases
activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT
activation response. Oncogene 18, 1–8 (1999).
48. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001).
49. Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373–
398 (2000).
50. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of
the human genome. Science 298, 1912–1934 (2002).
51. Woolfrey, J. R. & Weston, G. S. The use of computational methods in the discovery and design of kinase
inhibitors. Curr. Pharm. Des. 8, 1527–1545 (2002).
52. Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol.
3, 459–465 (1999).
53. Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and
basic fibroblast growth factor, tumor growth factor β1, platelet-derived endothelial cell growth factor,
placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Cancer Res. 57, 963–969 (1997).
54. Taylor, A. P. et al. Tumor-specific regulation of angiogenic growth factors and their receptors during
recovery from cytotoxic therapy. Clin. Cancer Res. 8, 1213–1222 (2002).
55. Kiselyov, A., Balakin, K. V. & Tkachenko, S. E. VEGF/VEGFR signalling as a target for inhibiting
angiogenesis. Expert Opin. Investig. Drugs 16, 83–107 (2007).
56. Underiner, T. L., Ruggeri, B. & Gingrich, D. E. Development of vascular endothelial growth factor receptor
(VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 11, 731–745
(2004).
57. Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity
relationships. Curr. Top. Med. Chem. 2, 973–1000 (2002).
58. Hennequin, L., Ple, P., Stokes, E. & McKerrecher, D. Quinozoline derivatives as angiogenesis inhibitors.
WO0047212 (2000).
59. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer
8, 579–591 (2008).
60. Clifford, S. C. & Maher, E. R. Von Hippel–Lindau disease: clinical and molecular perspectives. Adv.
Cancer Res. 82, 85–105 (2001).
61. Ouyang, B. et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or
BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12, 1785–1793 (2006).
62. Manley, P. W. et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase
inhibitors. J. Med. Chem. 45, 5687–5693 (2002).
63. Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial
growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64,
4931–4941 (2004).
64. Ghosh, S. et al. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an
inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against
breast cancer cells. Clin. Cancer Res. 4, 2657–2668 (1998).
65. Klohs, W. D., Fry, D. W. & Kraker, A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 9, 562–568
(1997).
66. Lawrence, D. .S. & Niu, J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol.
Ther. 77, 81–114 (1998).
67. Polverino, A. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial
growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces
regression in tumor xenografts. Cancer Res. 66, 8715–8721 (2006).
68. Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor
receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
69. Hennequin, L. F. et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure
activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med.
Chem. 45, 1300–1312 (2002).
70. Wedge, S. R. et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with
broad-spectrum antitumor efficacy. Cancer Res. 60, 970–975 (2000).
71. Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor
growth following oral administration. Cancer Res. 62, 4645–4655 (2002).
72. Wilhelm, S. M. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF–
MEK–ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 64, 7099–7109 (2004).
73. Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.
6, 327–338 (2009).
74. Steeghs, N. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule
angiogenesis inhibitor. Clin. Cancer Res. 14, 3470–3476 (2008).
75. Mross, K. et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination
irinotecan and sorafenib. Eur. J. Cancer 43, 55–63 (2007).
76. Moreno-Aspitia, A. et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously
exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial
N0336. J. Clin. Oncol. 27, 11–15 (2009).
77. Burstein, H. J. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in
patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin.
Oncol. 26, 1810–1816 (2008).
78. Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good
antitumor efficacy. Cancer Res. 68, 4774–4782 (2008).
79. Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent
VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol. 2009
[Epub ahead of print]. doi: 10.1007/s00280-009-1002-0
80. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy N. Engl. J. Med. 358, 1129–1136
(2008).
81. Borzilleri, R. M. et al. Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious
inhibitor of vascular endothelial growth factor receptor-2. J. Med. Chem. 49, 3766–3769 (2006).
82. Chen, H. X. & Cleck, J. N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev.
Clin. Oncol. 6, 465–477 (2009).
83. Ruel, R. et al. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine
(BMS-645737), an in vivo active potent VEGFR-2 inhibitor. Bioorg. Med. Chem. Lett. 18, 2985–2989
(2008).
84. Ruggeri, B. et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor
receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Cancer Res. 63, 5978–5991 (2003).
85. Trudel, S. et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of
t(4;14) multiple myeloma. Blood 105, 2941–2948 (2005).
86. Beebe, J. S. et al. Pharmacological characterization of CP-547632, a novel vascular endothelial growth
factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 63, 7301–7309 (2003).
87. Matsui, J. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities
against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Int. J. Cancer 122, 664–671 (2008).
88. Dev., I. K. et al. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of
VEGF and its receptor VEGFR2 in tumour models. Br. J. Cancer 91, 1391–1398 (2004).
89. Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m
ethyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor
inhibitor. J. Med. Chem. 51, 4632–4640 (2008).
90. Kumar, R. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a
multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6,
2012–2021 (2007).
91. Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Curr. Opin. Investig. Drugs 9, 1324–1335 (2008).
92. Nakamura, K. et al. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine
kinase that suppresses tumor angiogenesis and growth. Mol. Cancer Ther. 3, 1639–1649 (2004).
93. Nakamura, K. et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor
tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66,
9134–9142 (2006).
94. Garton, A. J. et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine
kinases with antitumor activity in mouse xenograft models. Cancer Res. 66, 1015–1024 (2006).
95. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine
kinase domain. EMBO J. 17, 5896–5904 (1998).
96. Tille, J. C. et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and
basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J. Pharmacol. Exp. Ther. 299,
1073–1085 (2001).
97. Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor
receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor
growth after oral administration. Cancer Res. 60, 2178–2189 (2000).
98. Muruganandham, M. et al. Preclinical evaluation of tumor microvascular response to a novel
antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol. Cancer
Ther. 5, 1950–1957 (2006).
99. Strawn, L. M. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540–3545 (1996).
100.
Fong, T. A. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor
receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple
tumor types. Cancer Res. 59, 99–106 (1999).
101.
Krystal, G. W. et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell
lung cancer cells. Cancer Res. 61, 3660–3668 (2001).
102.
Spiekermann, K. et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces
growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood
101, 1494–1504 (2003).
103.
Laird, A. D. et al. SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of
tumor vasculature and tumor regression in mice. FASEB J. 16, 681–690 (2002).
104.
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting
vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a
pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
105.
Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor
targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem.
46, 1116–1119 (2003).
106.
Cain, J. A., Grisolano, J. L., Laird, A. D. & Tomasson, M. H. Complete remission of
TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.
Blood 104, 561–564 (2004).
107.
Patyna, S. et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent
antiangiogenic and antitumor activity. Mol. Cancer Ther. 5, 1774–1782 (2006).
108.
Guo, X. N. et al. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine
kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biol. Ther. 4, 1125–1132 (2005).
109.
Zhong, L. et al. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of
VEGFR2 and PDGFRbeta. Cancer Biol. Ther. 5, 323–330 (2006).
110.
Amino, N. et al. YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor
receptor-2, is effective against paclitaxel resistant tumors. Biol. Pharm. Bull. 28, 2096–2101 (2005).
111.
Amino, N. et al. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2
tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin. Cancer
Res. 12, 1630–1638 (2006).
112.
Gendreau, S. B. et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor
receptor by EXEL-7647. Clin. Cancer Res. 13, 3713–3723 (2007).
113.
Whittles, C. E. et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2
tyrosine kinase activity. Microcirculation 9, 513–522 (2002).
114.
Rugo, H. S. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with
advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474–5483 (2005).
115.
Rosen, L. S. et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor,
in patients with advanced solid tumors. J. Clin. Oncol. 25, 2369–2376 (2007).
116.
Drevs, J. et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor
signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 3045–3054 (2007).
117.
Ryan, C. J. et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the
vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate
cancer (HRPC). Invest. New Drugs 25, 445–451 (2007).
118.
Holden, S. N. et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF
receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16, 1391–1397 (2005).
119.
Strumberg, D. et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a
review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12, 426–437
(2007).
120.
Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular
endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid
tumors. J. Clin. Oncol. 23, 965–972 (2005).
121.
Strumberg, D. et al. Phase I dose escalation study of telatinib (BAY 57–9352) in patients with
advanced solid tumours. Br. J. Cancer 99, 1579–1585 (2008).
122.
Sarker, D. et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral,
multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res.
14, 2075–2081 (2008).
123.
Cohen, R. B. et al. A phase I/randomized phase II, non-comparative, multicenter, open label trial of
CP-547, 632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line
treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother. Pharmacol. 60, 81–89
(2007).
124.
Mross, K. et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor
inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 41, 1291–1299 (2005).
125.
Kuenen, B. C. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416
in patients with solid tumors. J. Clin. Oncol. 20, 1657–1667 (2002).
126.
Salzberg, M. et al. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug
inducing its clearance. Invest. New Drugs 24, 299–304 (2006).
127.
Sessa, C. et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor
SU006668 by chronic oral dosing. Eur. J. Cancer 42, 171–178 (2006).
128.
Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
Invest. New Drugs 22, 459–466 (2004).
129.
Faivre, S. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget
tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25–35 (2006).